Neck circumference as a screening measure for identifying NAFLD among a group of academic employees in Bangkok, Thailand

Sapwarobol Suwimol1*, Tangkijvanich Pisit2, Avihingsanon Anchalee3, Kongruttanachok Narisorn4, Jantarakapde Jureeporn2, Jiamjarasrangsi Wiroj5

1 Medical Food Research Group, Nutrition and Dietetics Department, Faculty of Allied Health Sciences, Chulalongkorn University, Bangkok, Thailand, 2 Center of Excellence in Hepatitis and Liver Cancer, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand, 3 HIV-NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand, 4 Department of Laboratory Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand, 5 Department of Preventive and Social Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

* suwimol.sa@chula.ac.th

Abstract

Neck circumference (NC) reflects the fat deposition in upper body and has potential to be used as a predictor of Non-Alcoholic Fatty Liver Disease (NAFLD). Our objectives were to examine the association of NC with NAFLD prevalence, and to determine the optimal cut-off of NC in identifying the presence of NAFLD among the employees of an academic institution in Bangkok, Thailand. In this cross-sectional study, 635 employees of an academic institution underwent anthropometric measurement and transient elastography following an overnight fast. NAFLD was defined as a CAP value >238 dB.m-1. The NAFLD prevalence in men and women were 66.17% and 46.22%, respectively. The mean NCs for men and women with NAFLD were higher (38.53 ± 0.31 cm and 35.83 ± 0.48 cm, respectively) than those without NAFLD (33.58 ± 0.24 and 31.09 ± 0.14 cm, respectively) (p < 0.001). Metabolic markers including age, weight, BMI, NC, WC, WHR, FBS, triglycerides were significantly higher, HDL was significantly lower among participants with NAFLD compared to those without NAFLD (p<0.05). NC was independently associated with NAFLD among women with OR (95%CI) of 1.17 (1.05, 1.32). The optimal cut-offs of NC to predict NAFLD were 37.07 cm (sensitivity: 70.50%; specificity: 68.90%) and 32.07 cm (sensitivity: 70.70%; specificity: 62.10%), respectively for men and women. NC significantly correlated with NAFLD in women. The optimal cut-off points of 32 cm and 37 cm for men and women, which similar to Chinese populations. Therefore, it can be used as a cost-effective tool to predict NAFLD.

Trial Registration: Thai Clinical Trials Registry (TCTR20210329006)

Introduction

Evidence from several recent studies has shown the potential of neck circumference (NC) as an anthropometric measure that is well reflective for human health [1, 2]. Neck circumference...
is a surrogate for measuring upper body subcutaneous fat deposition, a predictor of metabolic syndrome (MetS), and a promising predictor of Non-Alcoholic Fatty Liver Disease (NAFLD) [3–5]. Compared to waist circumference as the surrogate for central obesity, NC measurement is easy and highly reproducible with little variation [6]. Its value is less likely influenced by age or associated with increasing age [7]. In addition, recent studies have also demonstrated that upper body subcutaneous adipose tissue has a stronger relationship with metabolic disorders than visceral adipose tissue (VAT) or central obesity [8].

Nonalcoholic fatty liver disease has now become the leading cause of chronic liver diseases worldwide [9]. As it strongly correlates with insulin resistance (IR), NAFLD is considered a risk factor for future development of metabolic syndrome and its complications such as type 2 diabetes mellitus and cardiovascular diseases [10]. Therefore, early detection and efficacious intervention at its primary stage will enhance prognosis and prevent such complications. At present, the most used method for NAFLD diagnosis is ultrasonography, which is not easy to organize and not cost-effective at community levels. Finding simpler and more effective indicators for population NAFLD screening is therefore an urgent need.

Several studies have examined the potential of neck circumference as the predictor of NAFLD in the adult population including four studies from the People Republic of China [4, 6, 11, 12] and one each from India [13] and Iran [14]. Three studies from China reported the optimal cut-off NC of 37.25 to 38.5 cm for male adults with the area under the curve (AUC) of 0.71–0.768, the sensitivity of 55.22 to 79.5% and specificity of 59.1 to 71%; and 32.9 to 34.5 cm for female adults with the AUC of 0.649–0.798, sensitivity of 62–79% and specificity of 67–77%. Iran’s study reported a slightly higher optimal cut-off of 39.25 cm for males (AUC 0.821, sensitivity 79% specificity 69%) and 34.85 cm for females (AUC 0.807, sensitivity 84%, specificity 64%). A study in India, among adults with pre-diabetes, reported a more gender-comparable optimal cut-off of 36.25 cm for males (AUC 0.551, sensitivity 72%, specificity 40%) and 35.25 cm for females (AUC 0.662, sensitivity 80%, specificity 62.7%). For the neck circumference to be a public health utility as a predictor of NAFLD, it should be widely applicable across global populations with comparable optimal cut-off among populations with similar race/ethnic backgrounds. In addition, Asian ethnicities are more susceptible to metabolic syndrome (MetS), type 2 diabetes and NAFLD than Europeans for equivalent levels of over-nutrition, because of body composition, particularly adiposity and muscle bulk difference [15].

In this study, we examined the potential of neck circumference in predicting NAFLD among the adult population in Thailand. Specifically, we aimed to: (a) examine the association of NC with NAFLD prevalence, and (b) determine the AUC, optimal cut-off, sensitivity, and specificity of neck circumference in identifying the presence of NAFLD and liver fibrosis (LF) among the employees of an academic institution in Bangkok, Thailand. We hypothesized that: (a) neck circumference can be used as a valid and independent predictor of NAFLD, and (b) the optimal cut-offs for both genders were similar to those reported in the Chinese population due to Thais sharing a similar Mongoloid ethnic background.

**Materials and methods**

**Study subjects**

This cross-sectional study was a part of the CU 100 years: A healthy liver and heart campaign —Hepatitis B, Hepatitis C, Cardiovascular risk and Non-alcoholic fatty liver disease (NAFLD) among staff members at Chulalongkorn University and King Chulalongkorn Memorial Hospital Bangkok, Thailand project. The project recruited 766 employees of an academic institution in Bangkok who participated in the annual physical check-up during 2019–2020.
Inclusion criteria were any staff currently working at the Chulalongkorn University or King Chulalongkorn Memorial Hospital who was older than 40 years. Participants with neck malformation or surgery history, thyroid dysfunction that may interfere with NC measurement, and those who were pregnant were excluded from the study.

Sample size calculation was conducted post-hoc based on the following formula [16]:
\[ n_{\text{control}} = \left( \frac{Z_{\alpha/2}^2 P (1-P)}{d^2} \right) \text{ and } n_{\text{total}} = \frac{n_{\text{control}}}{(1-\text{prevalence})}, \]
where \( n_{\text{control}} \) = number of non NAFLD, \( n_{\text{total}} \) = number of total subjects, \( P \) = expected specificity (0.71 for men and 0.77 for women) [4], \( d \) = allowable error (0.05), \( Z_{\alpha/2} \) = standard values for type I error at an \( \alpha \) level of 0.05 (1.96), and prevalence = prevalence of NAFLD among Thai adults (0.18 for men and 0.23 for women) [17]. This resulted in the required sample size of 388 for men and 353 for women. Our study subjects of 133 men and 502 women therefore indicated that the statistical power was limited for men and satisfactory for women.

A total 766 were recruited, 82 not contactable, 2 cancelled, 37 were below the age criteria, leaving 645 in the examination. However, eight were unsuccessfully examined, two were missing on gender, leaving 635 participants in the final analysis (Fig 1). The project was approved by the Ethics Committee of Chulalongkorn University Faculty of Medicine (IRB no. 546/59), and all subjects provided informed consent.

**Anthropometric measurements**

Anthropometric parameters, including weight (kg), height (cm), waist circumference (WC, cm) and hip circumference (HC, cm) were measured on the check-up day. Participants were requested to dress in light attire and were bare footed for weight measurement.

---

Fig 1. CONSORT flow diagram.

https://doi.org/10.1371/journal.pone.0263826.g001
mass index (BMI) was calculated by dividing body weight in kilograms by the square of the participant’s height in meters (kg/m$^2$). Waist circumference was measured horizontally to the nearest 1.0 mm using a standard measuring tape at a point right above the iliac crest on the mid-axillary line at minimal respiration. Hip circumference was measured in centimeters, at the level of maximum extension of the hip, with leg close together. Waist to Hip Ratio (WHR) was calculated as the ratio between WC and HC. Blood pressure was examined after 10 minutes rest in a sitting position on the upper left arm, and the systolic (SBP) and diastolic blood pressure (DBP) were recorded. Neck circumference was assessed around the inferior margin of the laryngeal prominence and perpendicular to the long axis of the neck, to the nearest 1.0 mm. by trained nurses. In men, NC was measured just below the laryngeal prominence, while participants standing upright and the head in the horizontal plane position with shoulders down [18].

**Biochemical assays**

Biochemical indicators including fasting blood glucose (FBG), total cholesterol (TC), triglycerides (TG), Low-density lipoprotein (LDL), high-density lipoprotein (HDL), aspartate aminotransferase (AST), and alanine aminotransferase (ALT) were obtained by the annual health check-up. On the day of check-up, fasting blood samples were taken from a vein puncture then it was immediately centrifuged (3,000 rpm) for 10 min at 4°C, and the serum was separated for further analysis. Fasting plasma glucose, TC, high-density lipoprotein-cholesterol (HDL-c), and TG were analyzed using the enzymatic method, while low-density lipoprotein-cholesterol (LDL-c) was estimated using the Friedewald equation (LDL-c = [total cholesterol] — [HDL-c] — [TG]/5). Hepatic steatosis index (HSI) was calculated as: 8 x (ALT/ aspartate aminotransferase ratio) + body mass index (+2, if female; +2, if diabetes mellitus) [19].

**Nonalcoholic Fatty Liver Disease (NAFLD) and liver fibrosis assessment**

Transient elastography was done with the FibroScan (Echosens, Paris, France) medical device, and the controlled attenuation parameter (CAP) was used to detect and quantify liver steatosis, while the liver stiffness measurement (LSM) was selected as the parameter to quantitate liver fibrosis [20]. After an overnight fast, the examination was performed using an M probe on the right lobe of the liver through intercostals spaces with the participants in dorsal decubitus with the right arm in maximal abduction by experienced technologists unaware of clinical data. In case of BMI $>30$ kg/m$^2$ or unreliable measurement from the M probe, the XL probe was used. Ten successful measurements were performed on each participant, and only cases with 10 successful acquisitions were taken into account for this study [21].

All scans were performed by the same investigator. The cut-off value for the diagnosis of liver steatosis was a CAP value $>238$ dB.m$^{-1}$, while the cut-off value for the diagnosis of significant liver fibrosis (F2) was liver stiffness $>7$ kPa [22]. The cut-off value for the diagnosis of liver steatosis (NAFLD) was a CAP value $>238$ dB.m$^{-1}$

There were several missing data including: 1 to 3 participants (0.16–0.47%) for age, SBP and DBP, cigarette smoking and alcohol drinking statuses; and 97 to 106 participants (15.28 to 16.69%) for FBS, TC, TG, HDL and LDL cholesterol, AST and ALT levels. Missing data for continuous variables were managed by cold-deck imputation where gender-specific mean values were used to assign to those participants for whom data were missing. Missing data for categorical data were managed by random overall imputation where a participant was selected at random from the total of participants, and the value for that person was assigned to all those participants for whom the information was missing [23].
Statistical analysis

All analyses were conducted separately for male and female participants. Continuous data were summarized and presented by mean (\(\bar{x}\)) and standard deviation (SD) in case of normal distribution, or by median and interquartile range (IQR) in case of skew distribution. Categorical data were summarized and presented by frequency and percentage. Group comparison between those with versus without NAFLD was conducted by unpaired t-test or Chi-square test (or Fisher’s Exact where appropriate) respectively for continuous and categorical data.

All analyses were conducted separately for male and female participants. Continuous data were summarized and presented by mean (\(\bar{x}\)) and standard deviation (SD) in case of normal distribution, or by median and interquartile range (IQR) in case of skew distribution. Categorical data were summarized and presented by frequency and percentage. Group comparison between those with versus without NAFLD was conducted by unpaired t-test or Chi-square test (or Fisher’s Exact where appropriate) respectively for continuous and categorical data.

Associations of neck circumference with the probability of NAFLD was then examined by logistic regression analyses using odds ratio (OR) and the corresponding 95% confidence interval (CI) as measure of association. Possibility for non-linearity of neck circumference and log odds NAFLD association was addressed by transforming neck circumference using a restricted cubic spline with three knots. Such transformation however did not reveal the evidence of non-linearity (as inferred from no significant different among the slopes of splines, detail not shown), the normal term of neck circumference was therefore used in the logistic regression analyses. Potential confounding effects of age, personal histories of HT, T2DM, dyslipidemia, cigarette smoking and alcohol consumption; BMI, waist circumference, SBP, DBP, FBS, TC, TG, LDL, HDL, AST, and ALT were taken into account by analyzing model 2. In MODEL I, all potential confounders were put into the model. In MODEL II, backward stepwise selection procedure was conducted and only the variables with the association p-value of <0.1 were left in the final model.

Performance of neck circumference in identifying NAFLD began by examining the distribution of observed and predicted NAFLD probabilities across the level of neck circumference. Then it was evaluated both in term of calibration and discrimination. Calibration was evaluated by using the Hosmer-Lemeshow goodness of fit test as well as observed proportions versus predicted probabilities. The intercept approaching zero and the slope approaching one reflects a perfect calibrated model [24].

Discrimination was evaluated by plotting the receiver operating characteristic (ROC) curves, and AUC with 95% confidence interval (CI) were calculated to explore the discriminative ability of neck circumference as diagnostic tests for detecting NAFLD and determine optimal sex-specific NC cutoffs in relation to NAFLD. The AUC of 0.5 was interpreted as “no discrimination”, 0.7 to 0.8 as “acceptable”, 0.8 to 0.9 as “excellent”, and more than 0.9 as “outstanding” [25].

The Youden index was used to determine the optimal cutoff points [26]. The STATA Version 15 [27] for Windows was used to perform all data analyses, and the statistical significance level was set at 0.05.

Results

Comparison between NAFLD and non-FLD participants

Of the 133 men and 502 women, 88 and 232 had NAFLD with the prevalence of 66.17 and 46.22% respectively. Concerning LF, 6 men and 12 women had such conditions, with the prevalence of 4.51 and 2.39% respectively.
Group comparison between participants with and without NAFLD showed that neck circumferences were significantly larger among those with NAFLD, with the mean (SD) of 38.53 (0.31) versus 35.83 (0.48) centimeters for men \( (p < .0001) \) and 33.58 (0.24) versus 31.08 (0.14) centimeters for women \( (p < .0001) \) (Table 1). Those with NAFLD also were older, and had higher values of anthropometric measures (weight and BMI, WC, HC, neck to height ratio and waist to hip ratio), blood pressure (SBP and DBP), fasting blood glucose, and liver function tests (AST and ALT). They had higher levels of triglyceride and lower levels of HDL cholesterol. NAFLD had higher personal histories of HT and T2DM than those without NAFLD, particularly among women. In addition, men, and women with NAFLD has a significantly higher value of HSI.

Table 1. Comparison between participants with and without NAFLD, stratified by gender.

| Variables                        | Women (n = 502) | Men (n = 133) |
|----------------------------------|----------------|--------------|
|                                  | NAFLD (n = 232) | Non_FLD (n = 270) | p-value | NAFLD (n = 88) | Non_FLD (n = 45) | p-value |
| Mean (SD)                        | Mean (SD) | Mean (SD) | Mean (SD) |                       | Mean (SD) | Mean (SD) |                                            |
| Age (years)                      | 52.64 (0.45) | 50.41 (0.54) | 0.0014 | 49.62 (0.76) | 49.78 (1.00) | 0.903 |
| Height (cm)                      | 157.04 (0.32) | 156.99 (0.35) | 0.9083 | 169.34 (0.63) | 168.09 (0.88) | 0.2496 |
| Weight (kg)                      | 65.91 (0.70) | 59.14 (3.35) | 0.0345 | 77.34 (1.44) | 64.54 (1.20) | <0.001 |
| Neck circumference (cm)          | 33.58 (0.24) | 31.08 (0.14) | <0.001 | 38.53 (0.31) | 35.83 (0.48) | <0.001 |
| Waist circumference (cm)         | 87.21 (0.61) | 76.53 (0.60) | <0.001 | 93.88 (1.35) | 83.06 (1.34) | <0.001 |
| Hip circumference (cm)           | 100.91 (0.52) | 94.03 (0.47) | <0.001 | 101.59 (0.87) | 95.31 (0.87) | <0.001 |
| Body mass index (kg/m²)          | 26.70 (0.45) | 24.15 (1.51) | <0.001 | 26.98 (0.50) | 22.88 (0.45) | <0.001 |
| Neck to height ratio             | 0.214 (0.002) | 0.198 (0.001) | <0.001 | 0.228 (0.002) | 0.213 (0.003) | 0.0001 |
| Waist to hip ratio               | 0.863 (0.003) | 0.813 (0.004) | <0.001 | 0.922 (0.008) | 0.871 (0.011) | 0.0004 |
| Systolic blood pressure (mm Hg)  | 128.59 (1.04) | 117.31 (1.07) | <0.001 | 131.77 (1.40) | 122.84 (2.02) | 0.0004 |
| Diastolic blood pressure (mm Hg) | 81.23 (0.63) | 76.37 (0.60) | <0.001 | 84.48 (0.98) | 81.73 (1.41) | 0.1072 |
| Platelet count (x 10³/μL)        | 297.97 (3.94) | 277.94 (3.95) | 0.0004 | 262.24 (4.74) | 244.83 (6.53) | 0.0336 |
| Mean corpuscular volume (fL)‡    | 87.60 (10.40) | 88.20 (10.15) | 0.5887 | 87.90 (8.70) | 88.00 (7.60) | 0.3929 |
| Fasting blood glucose (mg/dL)     | 98.42 (1.60) | 90.39 (1.04) | 0.0001 | 101.08 (3.05) | 95.58 (4.19) | 0.2929 |
| Total cholesterol (mg/dL)         | 220.46 (2.12) | 219.88 (2.50) | 0.8582 | 213.70 (3.78) | 209.70 (7.93) | 0.6059 |
| Triglycerides (mg/dL)             | 119.54 (3.80) | 92.36 (2.61) | <0.001 | 143.96 (7.94) | 98.40 (7.16) | 0.0003 |
| LDL cholesterol (mg/dL)           | 139.14 (1.85) | 137.86 (2.20) | 0.6539 | 136.03 (3.61) | 132.80 (7.64) | 0.6648 |
| HDL cholesterol (mg/dL)           | 57.41 (0.70) | 63.55 (0.86) | <0.001 | 48.88 (1.11) | 57.22 (2.35) | 0.0004 |
| Aspartate aminotransferase (U/L)‡ | 23.37 (0.97) | 19.90 (0.38) | 0.0017 | 24.20 (0.80) | 23.18 (1.00) | 0.4419 |
| Alanine aminotransferase (U/L)‡   | 23.30 (0.97) | 19.83 (0.38) | 0.0018 | 25.21 (0.83) | 23.97 (1.06) | 0.3708 |
| ALT/AST ratio‡                    | 1 (0)       | 1 (0)       | 0.7597 | 1 (0)       | 1 (0)       | 0.7750 |
| Cigarette smoking status†         | 11 (4.07)    | 4 (1.72)    | 0.188  | 12 (13.64)  | 6 (13.33)   | 0.100  |
| Alcohol drinking status†          | 28 (10.37)   | 37 (15.95)  | 0.082  | 32 (36.36)  | 14 (31.11)  | 0.570  |
| Personal history of hypertension† | 57 (21.11)   | 25 (10.78)  | 0.002  | 11 (12.5)   | 4 (8.89)    | 0.733  |
| Personal history of diabetes†     | 33 (12.22)   | 8 (3.45)    | 0/0    | 9 (10.23)   | 6 (13.33)   | 0.576  |
| Personal history of dyslipidemia† | 57 (21.11)   | 41 (17.67)  | 0.367  | 11 (12.50)  | 4 (8.89)    | 0.773  |
| Significant Liver stiffness (>7 kPa)† | 1 (0.43) | 11 (4.07)    | 0.008  | 5 (5.68)    | 1 (2.22)    | 0.663  |
| Hepatic steatosis index (HSI)      | 36.93 (0.27) | 32.79 (0.23) | 0.0001 | 34.91 (0.53) | 30.84 (0.47) | 0.0001 |
| HBS Ag positive†                  | 7 (2.59)     | 6 (2.59)    | 1.000  | 3 (3.41)    | 3 (6.67)    | 0.406  |
| Anti HCV positive†                | 1 (0.37)     | 2 (0.86)    | 0.598  | 0 (0)       | 1 (2.22)    | 0.338  |

† median (interquartile range or IQR)  
‡ median (interquartile range or IQR)  
ALT/AST ratio = Aspartate aminotransferase/Alanine aminotransferase ratio.  
HBS Ag = Hepatitis B virus surface antigen  
Anti HCV = Antibody against hepatitis C virus.

https://doi.org/10.1371/journal.pone.0263826.t001
Association between metabolic syndrome parameters and NAFLD

Metabolic syndrome parameters including BMI, WC, SBP, DBP, FBG, TG, and HDL were associated with liver steatosis among women. For men, however, no correlation of FBG, DBP and liver steatosis observed possibly due to its limited sample size. In addition, HSI showed a strong correlation with liver steatosis in both men and women (Table 2).

Association between neck circumference and NAFLD

Logistic regression analyses show that neck circumference was significantly and independently associated with NAFLD among women (Table 3), with the OR (95%CI) of 1.17 (1.05, 1.32) for the best fitted model (Model II, as inferred from the Hosmer-Lemeshow goodness of fit test result). For men, however, neck circumference was significantly associated with NAFLD only in the unadjusted (or crude) analytical result, possibly due to its small sample size.

Plotting of the NAFLD probability by neck circumference level showed that NAFLD probabilities increased progressively according to neck circumference level, with the lean s-shape pattern of association in both women and men (Fig 2).

Distribution patterns of both the observed and expected NAFLD probabilities were well consistent with each other, particularly for women. This was confirmed by the calibration plots (Fig 3), the results of which revealed negligible departure from zero of the calibration in the large (CITL) values and trivial departure from one for the slopes. The expected NAFLD probability for women was slightly less than the observed probability, while it was contrary for men.

Concerning the accuracy of neck circumference to discriminate between those with from those without NAFLD, the AUC results were between 0.7 to 0.8 and thus indicated this was acceptable, with the suggested optimal cut-offs of 32.07 and 37.07 cm respectively for women and men (Table 4). The corresponding sensitivity and specificity values were 70.70 and 62.10% respectively for women, and 70.50 and 68.90% for men.

Discussion

The relationships between NAFLD and NC, metabolic and anthropometric measurements were evaluated in this study. As the prevalence of NAFLD is high and increasing, its clinical

Table 2. Correlation between the controlled attenuation parameter (CAP) quantifying liver steatosis and metabolic syndrome parameters, stratified by gender.

| Parameters                        | Women       | Men          |
|-----------------------------------|-------------|--------------|
|                                  | r (95%CI)   | p-value      | r (95%CI)   | p-value      |
| Body mass index (kg/m²)           | 0.55 (0.49, 0.61) | 0.001        | 0.51 (0.38, 0.63) | 0.001       |
| Neck circumference (cm)           | 0.43 (0.36, 0.50) | 0.001        | 0.46 (0.31, 0.58) | 0.001       |
| Waist circumference (cm)          | 0.57 (0.51, 0.63) | 0.001        | 0.53 (0.40, 0.65) | 0.001       |
| Systolic blood pressure (mm Hg)   | 0.38 (0.30, 0.45) | 0.001        | 0.29 (0.13, 0.44) | 0.001       |
| Diastolic blood pressure (mm Hg)  | 0.30 (0.22, 0.38) | 0.001        | 0.14 (-0.03, 0.30) | 0.1125      |
| Fasting blood glucose (mg/dL)     | 0.25 (0.17, 0.33) | 0.001        | 0.12 (-0.05, 0.29) | 0.1671      |
| Total cholesterol (mg/dL)         | 0.05 (-0.04, 0.14) | 0.6809      | -0.05 (-0.22, 0.12) | 0.5758      |
| Triglycerides (mg/dL)             | 0.31 (0.23, 0.39) | 0.001        | 0.33 (0.17, 0.48) | 0.001       |
| LDL cholesterol (mg/dL)           | 0.08 (-0.01, 0.17) | 0.4013      | -0.08 (-0.25, 0.09) | 0.3337      |
| HDL cholesterol (mg/dL)           | -0.33 (-0.40, -0.25) | 0.001      | -0.25 (-0.41, -0.09) | 0.004       |
| Hepatic steatosis index (HSI)     | 0.56 (0.49, 0.61) | 0.001        | 0.49 (0.35, 0.61) | 0.001       |

r = Pearson’s correlation coefficient CI = Confidence interval.

https://doi.org/10.1371/journal.pone.0263826.t002
and economic burden will become tremendous [9]. As NAFLD is considered the liver indicator of metabolic syndrome [28] and the most common indicator for liver transplantation [29]; simple tools for the early detection of NAFLD are therefore imperative as the first step in the endeavor to ameliorate its enormous public health impact, especially in resource limited settings. In this study we demonstrated that NC could be used as one of such tools. In addition, NC is the most discriminative indicator that can predict the development of NAFLD. Its discriminative ability to differentiate between those with and without NAFLD was acceptable, as indicated by the AUC of approximately 0.75. In addition, HSI also provide good estimates of development of NAFLD. The use of HSI is also a reasonable indicator for NAFLD prediction. This study identified optimal cut-offs for NC of about 32 cm for women and 37 cm for men, which was comparable to those identified for Chinese adults sharing a similar ethnic background to the Thai population. That may also support the generalizability of using NC as

Table 3. Association between neck circumference and NAFLD, stratified by gender.

| MODEL    | OR (95%CI) | p-value | GOF | OR (95%CI) | p-value | GOF |
|----------|------------|---------|-----|------------|---------|-----|
| Crude Model | 1.50 (1.37, 1.65) | 0.001 | 0.0011 | 1.39 (1.19, 1.63) | 0.001 | 0.001 |
| MODEL I | 1.16 (1.03, 1.31) | 0.014 | 0.0231 | 1.12 (0.86, 1.46) | 0.389 | 0.0398 |
| MODEL II | 1.17 (1.05, 1.32) | 0.006 | 0.2817 | 1.07 (0.87, 1.32) | 0.527 | 0.3062 |

GOF = Hosmer-Lemeshow goodness of fit test (p-value)  OR = Odds ratio.
MODEL I: adjusted for age; personal histories of hypertension, diabetes and dyslipidemia; cigarette smoking and alcohol drinking status; body mass index, waist circumference, systolic and diastolic blood pressures, fasting blood glucose, total cholesterol, triglyceride, HDL and LDL cholesterol, aspartate aminotransferase and alanine aminotransferase levels.
MODEL II: adjusted for age; cigarette smoking and alcohol drinking status; waist circumference, systolic blood pressure, and fasting blood glucose levels; these variables were obtained by a backward stepwise selection procedure, leaving those with p< 0.1 in the final model.

![Fig 2. Distribution of the observed and predicted probabilities of having non-alcoholic fatty liver disease (NAFLD) across neck circumference level among for (a) female and (b) male participants. Thick line represents the expected probability, hollow circle represents the observed probability, shade represents the 95% confidence interval of the expected probability.](https://doi.org/10.1371/journal.pone.0263826.g002)
an appropriate screening tool in the early steps for NAFLD detection. Previous studies indicated that NC reflects the upper-body fat deposition and contributes to the proportion of systemic free fatty acids (FFA) which are involved in pathogenesis of NAFLD [30]. Our evidence was strong for women, while this was not the case for men, possibly due to the limited sample size. Similarly, previous studies demonstrated that NC has a highest predictive value to predict NAFLD in women, whereas WC has a highest predictive value in men [12].
Our findings showed a high NAFLD prevalence of 66.17% and 46.22% respectively for men and women aged greater than 40 years. The high prevalence of MetS was also recognized in the current study. This might be because of a high prevalence of overweight and obesity in both men and women who participated in the study. As reported, the prevalence of obesity in Thailand keeps increasing from 33.9% in 2012 to 44.8% in 2018 even in rural areas [31]. With a sedentary lifestyle of our participants, the obesity prevalence is higher than expected.

In addition, age and obesity are significant risk factors of NAFLD. Therefore, the high prevalence of NAFLD observed in this study might be related to a high prevalence of obesity and age of the study populations. As a previous study indicated, NC reflects abdominal fat accumulation and obesity, it is therefore related to fatty liver and hepatitis [32]. In addition, it was demonstrated that NC significantly correlates with plasminogen activator inhibitor 1, and leads to inflammation of the liver and cardiovascular disease [33, 34].

In this study, weight, BMI, NC, WC, WHR, FBS, triglycerides, ALT, AST were significantly higher whereas HDL was significantly lower among participants with NAFLD compared to those without NAFLD, which was in accordance with a previous study [35]. Additionally, a strong relationship between MetS parameters and the prevalence of NAFLD existed in both genders. Among women participants, NAFLD prevalence was higher in participants who reported hypertension and diabetes. Similarly, a previous study also reported that NAFLD prevalence was two-fold higher in hypertensive individuals than in non-hypertensive individuals [36]. Meanwhile, diabetes shows a directional relationship with NAFLD since diabetes increases the risk of NAFLD and NAFLD worsens hyperglycemia in diabetic patients [37, 38]. This could attribute to the role of intrahepatic fat in the development of insulin resistance and MetS. In NAFLD, excessive fat accumulation in the liver increases the mobilization of free fatty acids (FFAs) and consequently promotes insulin resistance [39]. Elevated reflux FFAs can also reduce adiponectin secretion thus stimulating triglycerides and VLDL synthesis in the hepatocytes. In addition, FFAs overruns in the pancreas may cause lipotoxicity and lead to β-cell dysfunction and hyperglycemia [39].

The limitations of the study were that our participants were employees of the hospital and university in the center of Bangkok, thus the results from this study could not be extrapolated to the Thai population countrywide. A regional multi-center study is recommended for future study. In addition, this study corrected blood indicators from a routine check-up which was

| Parameter      | Women               | Men               |
|----------------|---------------------|-------------------|
|                | Mean (95% CI)       | Mean (95% CI)     |
| AUC            | 0.757 (0.719, 0.795) | 0.759 (0.673, 0.846) |
| Cut-off        | 32.07 (31.62, 32.51) | 37.07 (36.20, 37.93) |
| Sensitivity (%)| 70.70 (64.90, 76.10) | 70.50 (59.80, 79.70) |
| Specificity (%)| 62.10 (55.50, 68.30) | 68.90 (53.40, 81.80) |
| PPV (%)        | 68.50 (62.70, 73.90) | 81.60 (71.00, 89.50) |
| NPV (%)        | 64.60 (57.90, 70.80) | 54.40 (40.70, 67.60) |
| LR+            | 1.86 (1.56, 2.24)   | 2.26 (1.44, 3.57)  |
| LR-            | 0.47 (0.38, 0.58)   | 0.43 (0.29, 0.63)  |
| Odds ratio     | 3.96 (2.73, 5.74)   | 5.28 (2.44, 11.44) |

AUC = area under the receiver operating characteristic (ROC) curve; CI = confidence interval; LR+ = likelihood ratio for positive results; LR- = likelihood ratio for negative results; NPV = negative predictive value; PPV = positive predictive value.

https://doi.org/10.1371/journal.pone.0263826.t004
approximately three months before elastography and the NC examination. Moreover, liver biopsy, which is the gold standard of liver steatosis quantification, or magnetic resonance imaging (MRI)-based modality might be better indicators to diagnose patients with NAFLD than the performance of CAP. However, in a recent meta-analysis, it has been shown that CAP correlates well with the amount of steatosis assessed by liver biopsy. Additionally, the etiology of liver disease, including HBV and HCV, fibrosis staging, and diabetes are not associated with the discrepancies between CAP and histological assessment of liver steatosis [40].

**Conclusion**

This study concluded that NC is associated with NAFLD prevalence and can be used as a strong and accurate measurement to predict a prognosis of NAFLD and MetS in a cost-effective manner. The optimal cut-offs for NC to identifying the presence of NAFLD are 32 cm and 37 cm for women and men, respectively. Those NC cut-offs for NAFLD prediction are almost similar to those reported among Chinese populations. Also, NAFLD had significantly higher metabolic markers including age, weight, BMI, NC, WC, WHR, FBS, triglycerides but HDL was significantly lower among participants with NAFLD compared to those without NAFLD.

**Supporting information**

S1 Table. Association between hepatic steatosis index (HIS) and NAFLD, stratified by gender.

(DOCX)

S1 Fig. Distribution of the observed and predicted probabilities of having non-alcoholic fatty liver disease (NAFLD) across hepatic steatosis index (HSI) level among for (a) female and (b) male participants. Thick line represents the expected probability, hollow circle represents the observed probability, shade represents the 95% confidence interval of the expected probability.

(DOCX)

S1 File. Dataset of the study.

(XLS)

**Acknowledgments**

The author acknowledges the contributions of all participants for their enthusiasm and cooperation.

**Author Contributions**

Conceptualization: Sapwarobol Suwimol.

Data curation: Tangkijvanich Pisit, Avihingsan Anchalee, Kongruttanachok Narisorn, Jantaratapakde Jureeporn, Jiamjarasrangsi Wiroj.

Formal analysis: Jiamjarasrangsi Wiroj.

Funding acquisition: Kongruttanachok Narisorn.

Investigation: Sapwarobol Suwimol, Tangkijvanich Pisit, Jantaratapakde Jureeporn.

Methodology: Sapwarobol Suwimol.

Project administration: Sapwarobol Suwimol.

Resources: Jantaratapakde Jureeporn.
Software: Jiamjarasrangsi Wiroj.

Supervision: Tangkijvanich Pisit.

Visualization: Avihingsanon Anchalee.

Writing – original draft: Sapwarobol Suwimol, Jiamjarasrangsi Wiroj.

Writing – review & editing: Sapwarobol Suwimol, Avihingsanon Anchalee, Kongruttanachok Narisorn.

References

1. Ataie-Jafari A, Namazi N, Djalalini a S, Chaghamir zayi P, Abdar ME, Zadehe SS, et al. Neck circumference and its association with cardiometabolic risk factors: a systematic review and meta-analysis. Diabetol Metab Syndr. 2018; 10(1):72. https://doi.org/10.1186/s13098-018-0373-y PMID: 30288175

2. Kroll C, Mastroeni SS, Czarnobay SA, Ekwaru JP, Veugelers PJ, Mastroeni MF. The accuracy of neck circumference for assessing overweight and obesity: a systematic review and meta-analysis. Ann Hum Biol. 2017; 44(8):667–77. https://doi.org/10.1080/03014460.2017.1390153 PMID: 29037078

3. Ben-Noun L, Laor A. Relationship of neck circumference to cardiovascular risk factors. Obesity Res. 2003; 11(2):226–31. https://doi.org/10.1038/oby.2003.35 PMID: 12582218

4. Huang B-x, Zhu M-f, Wu T, Zhou J-y, Liu Y, Chen X-l, et al. Neck circumference, along with other anthropometric indices, has an independent and additional contribution in predicting fatty liver disease. PLoS One. 2015; 10(2):e0118071. https://doi.org/10.1371/journal.pone.0118071 PMID: 26779378

5. Li Q, Wang N, Han B, Chen Y, Zhu C, Chen Y, et al. Neck circumference as an independent indicator to non-alcoholic fatty liver disease in non-obese men. Nutr Metab. 2015; 12(1):63. https://doi.org/10.1186/s12986-015-0060-z PMID: 25679378

6. Jian C, Xu Y, Ma X, Shen Y, Wang Y, Bao Y. Neck Circumference is an Effective Supplement for Non-alcoholic Fatty Liver Disease Screening in a Community-Based Population. J Endocrinol. 2020;2020.

7. Moura B, Santos I, Goulart A, Schmidt M, Lotufo P, Bensendor I, et al. Neck and waist circumference values according to sex, age, and body-mass index: Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). Braz J Med Biol Res. 2020; 53(10).

8. Patel P, Abate N. Role of subcutaneous adipose tissue in the pathogenesis of insulin resistance. J Obes. 2013; 2013:489187. https://doi.org/10.1155/2013/489187 PMID: 23691287

9. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016; 64(1):73–84. https://doi.org/10.1002/hep.28431 PMID: 26707365

10. Lonardo A, Ballestri S, Marchesini G, Angulo P, Loria P. Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. Dig Liver Dis. 2015; 47(3):181–90. https://doi.org/10.1016/j.dld.2014.09.020 PMID: 25739820

11. Lin S, Xian Y, Liu Y, Cai W, Song J, Zhang X. Risk factors and community intervention for nonalcoholic fatty liver disease in community residents of Urumqi, China. Medicine (Baltimore). 2018; 97(9):e0021. https://doi.org/10.1097/MD.0000000000001024 PMID: 29489647

12. Hu Y, Chen J, Yang L, Chen P, Li J, Chen L, et al. The value of neck circumference (NC) as a predictor of non-alcoholic fatty liver disease (NAFLD). J Clin Transl Endocrinol. 2014; 1(4):133–9. https://doi.org/10.1016/j.jcte.2014.07.001 PMID: 29190994

13. Mondal SA, Dutta D, Kumar M, Singh P, Basu M, Selvan C, et al. Neck Circumference to Height Ratio is a Reliable Predictor of Liver Stiffness and Nonalcoholic Fatty Liver Disease in Prediabetes. Indian J Endocrinol Metab. 2018; 22(3):347–54. https://doi.org/10.4103/ijem.IJEM_31_18 PMID: 30097262

14. Salmanroghani H, Salmanroghani R, Nourian M, Khayam K, Lahmi F, Iravani S. Evaluation of neck circumference as an easy and reliable predictor for non-alcoholic fatty liver disease. Turk J Gastroenterol. 2019; 30(2):163–70. https://doi.org/10.5152/tjg.2018.18004 PMID: 30541716

15. Farrell GC, Wong VW, Chitturi S. NAFLD in Asia—as common and important as in the West. Nat Rev Gastroenterol Hepatol. 2013; 10(5):307–18. https://doi.org/10.1038/nrgastro.2013.34 PMID: 23458891

16. Hajian-Tilaki K. Sample size estimation in diagnostic test studies of biomedical informatics. J Biomed Inform. 2014; 48:193–204. https://doi.org/10.1016/j.jbi.2014.02.013 PMID: 24582925

17. Summart U, Thinkhamrop B, Chamadon N, Khuntikeo N, Sonthammat W, Kim CS. Gender differences in the prevalence of nonalcoholic fatty liver disease in the Northeast of Thailand: a population-based cross-sectional study. F1000Research. 2017;6. https://doi.org/10.12688/f1000research.12417.2 PMID: 29039809
18. Luo Y, Ma X, Shen Y, Xu Y, Xiong Q, Zhang X, et al. Neck circumference as an effective measure for identifying cardio-metabolic syndrome: a comparison with waist circumference. Endocrine. 2017; 55 (3):822–30. https://doi.org/10.1007/s12020-016-1151-y PMID: 27798813

19. Lee J-H, Kim D, Kim HJ, Lee C-H, Yang JI, Kim W, et al. Hepatic steatos index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis. 2010; 42(7):503–8. https://doi.org/10.1016/j.dld.2009.08.002 PMID: 19766548

20. Mikolasevic I, Orlc L, Franjic N, Hauser G, Stimac D, Milic S. Transient elastography (FibroScan®) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease—Where do we stand? World J Gastroenterol. 2016; 22(32):7236–51. https://doi.org/10.3748/wjg.v22.i32.7236 PMID: 27621571

21. Boursier J, Zarski JP, de Ledinghen V, Rousselet MC, Sturm N, Lebail B, et al. Determination of reliability criteria for liver stiffness evaluation by transient elastography. Hepatology. 2013; 57(3):1182–91. https://doi.org/10.1002/hep.25993 PMID: 22899556

22. Sasso M, Beaugrand M, de Ledinghen V, Douvin C, Marcellin P, Poupon R, et al. Controlled attenuation parameter (CAP): a novel VCTE™ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol. 2010; 36(11):1825–35. https://doi.org/10.1016/j.ultrasmedbio.2010.07.006 PMID: 20970345

23. Aday LA, Comelus LJ. Designing and conducting health surveys: a comprehensive guide. 2nd ed. San-Francisco, California: Jossey-Bass Publishers; 1996.

24. Steyerberg EW, Vickers AJ, Cook NR, Gerds T, Gonen M, Obuchowski N, et al. Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology. 2010; 21 (1):128–38. https://doi.org/10.1097/EDE.0b013e3181e30fb2 PMID: 20010215

25. Hosmer DW, Lemeshow S. Applied Logistic Regression. 2nd ed. Shewhart WA, Wilks SS, editors. New York: John Wiley and Sons; 2000.

26. Asano J, Hirakawa A, Hamada C. A stepwise variable selection for a Cox proportional hazards cure model with application to breast cancer data. Japanese Journal of Biometrics. 2013; 34(1):21–34.

27. StataCorp. Stata Statistical Software: Release 15. College Station, TX. StataCorp LLC; 2017.

28. Augustin S, Graupera I, Caballera J. Non-alcoholic fatty liver disease: A poorly known pandemic. Med Clin (Barc). 2017; 149(12):542–8. https://doi.org/10.1016/j.medcli.2017.06.026 PMID: 28751080

29. Hu XY, Li Y, Li LQ, Zheng Y, Lv JH, Huang SC, et al. Risk factors and biomarkers of non-alcoholic fatty liver disease: an observational cross-sectional population survey. BMJ open. 2018; 8(4):e019974. https://doi.org/10.1136/bmjopen-2017-019974 PMID: 29626047

30. Li Q, Wang N, Han B, Chen Y, Zhu C, Chen Y, et al. Neck circumference as an independent indicator to non-alcoholic fatty liver disease in non-obese men. Nutr Metab. 2015; 12(1):63. https://doi.org/10.1186/s12986-015-0060-z PMID: 26719755

31. Sakboonyarat B, Pornponsawad C, Sangkool T, Panmanas C, Kesomphaet N, Tangkhongtavi N, et al. Trends, prevalence and associated factors of obesity among adults in a rural community in Thailand: serial cross-sectional surveys, 2012 and 2018. BMC Public Health. 2020; 20(1):850. https://doi.org/10.1186/s12889-020-09004-w PMID: 32493314

32. Fantin F, Comelot G, Rossi AP, Grison E, Zoico E, Mazzali G, et al. Relationship between neck circumference, insulin resistance and arterial stiffness in overweight and obese subjects. Eur J Prev Cardiol. 2017; 24(14):1532–40. https://doi.org/10.1177/2047487317721655 PMID: 28728486

33. Stojiljkovic MP, Lopes HF, Zhang D, Morrow JD, Goodfriend TL, Egan BM. Increasing plasma fatty acids elevates F2-isoprostanes in humans: implications for the cardiovascular risk factor cluster. J Hypertens. 2002; 20(6):1215–21. https://doi.org/10.1097/00004872-200206000-00036 PMID: 12023694

34. Carazo A, León J, Casado J, Gila A, Delgado S, Martín A, et al. Hepatic expression of adiponectin receptors increases with non-alcoholic fatty liver disease progression in morbid obesity in correlation with glutathione peroxidase 1. Obes Surg. 2011; 21(4):492–500. https://doi.org/10.1007/s11695-010-0353-2 PMID: 21240660

35. Fan JG, Saibara T, Chitturi S, Kim BI, Sung JJ, Chutaputti A. What are the risk factors and settings for non-alcoholic fatty liver disease in Asia-Pacific? J Gastroenterol Hepatol. 2007; 22(6):794–800. https://doi.org/10.1111/j.1440-1746.2007.04952.x PMID: 17498218

36. Donati G, Stagni B, Piscaglia F, Venturoli N, Morselli-Labate AM, Rasciti L, et al. Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes: role of insulin resistance. Gut. 2004; 53(7):1020. https://doi.org/10.1136/gut.2003.027086 PMID: 15194655

37. Tomah S, Alkhouri N, Hamdy O. Nonalcoholic fatty liver disease and type 2 diabetes: where do Diabetologists stand? Clin Diabetes Endocrinol. 2020; 6(1):9. https://doi.org/10.1186/s40842-020-00097-1 PMID: 32518675
38. Xia M-F, Bian H, Gao X. NAFLD and Diabetes: Two Sides of the Same Coin? Rationale for Gene-Based Personalized NAFLD Treatment. Front Pharmacol. 2019; 10:877. https://doi.org/10.3389/fphar.2019.00877 PMID: 31447675

39. Godoy-Matos AF, Silva Júnior WS, Valerio CM. NAFLD as a continuum: from obesity to metabolic syndrome and diabetes. Diabetol Metab Syndr. 2020; 12:60. https://doi.org/10.1186/s13098-020-00570-y PMID: 32684985

40. Karlas T, Petroff D, Sasso M, Fan JG, Mi YQ, de Lédinghen V, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol. 2017; 66 (5):1022–30. https://doi.org/10.1016/j.jhep.2016.12.022 PMID: 28039099